Literature DB >> 30462209

Adipocyte-Specific GH Receptor-Null (AdGHRKO) Mice Have Enhanced Insulin Sensitivity With Reduced Liver Triglycerides.

Edward O List1,2, Darlene E Berryman1,3, Mathew Buchman1,4, Caitlin Parker1,4, Kevin Funk1, Stephen Bell1,3, Silvana Duran-Ortiz1, Yanrong Qian1, Jonathan A Young1, Cody Wilson1, Julie Slyby1, Savannah McKenna1, Elizabeth A Jensen1, John J Kopchick1,3.   

Abstract

Global GH receptor-null or knockout (GHRKO) mice have been extensively studied owing to their unique phenotype (dwarf and obese but remarkably insulin sensitive and long-lived). To better understand the influence of adipose tissue (AT) on the GHRKO phenotype, we previously generated fat-specific GHRKO (FaGHRKO) mice using the adipocyte protein-2 (aP2) promoter driving Cre expression. Unlike global GHRKO mice, FaGHRKO mice are larger than control mice and have an increase in white AT (WAT) mass and adipocyte size as well as an increase in brown AT mass. FaGHRKO mice also have an unexpected increase in IGF-1, decrease in adiponectin, no change in insulin sensitivity or liver triglyceride content, and a decreased lifespan. Extensive analysis of the aP2 promoter/enhancer by multiple laboratories has revealed expression in nonadipose tissues, confounding interpretation of results. In the current study, we used the adiponectin promoter/enhancer to drive Cre expression, which better targets mature adipocytes, and generated a new line of adipocyte-specific GHRKO (AdGHRKO) mice. AdGHRKO mice have an increase in adipocyte size and WAT depot mass in all depots except male perigonadal, a WAT accumulation pattern similar to FaGHRKO mice. Likewise, adiponectin levels and WAT fibrosis are decreased in both tissue-specific mouse lines. However, unlike FaGHRKO mice, AdGHRKO mice have no change in IGF-1 levels, improved glucose homeostasis, and reduced liver triglycerides. Thus, AdGHRKO mice should be valuable for future studies assessing the contribution of adipocyte GHR signaling in long-term health and lifespan.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 30462209      PMCID: PMC6304108          DOI: 10.1210/en.2018-00850

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  45 in total

1.  Increased fibrosis: A novel means by which GH influences white adipose tissue function.

Authors:  Lara A Householder; Ross Comisford; Silvana Duran-Ortiz; Kevin Lee; Katie Troike; Cody Wilson; Adam Jara; Mitchell Harberson; Edward O List; John J Kopchick; Darlene E Berryman
Journal:  Growth Horm IGF Res       Date:  2017-12-20       Impact factor: 2.372

2.  Growth hormone treatment of abdominally obese men reduces abdominal fat mass, improves glucose and lipoprotein metabolism, and reduces diastolic blood pressure.

Authors:  G Johannsson; P Mårin; L Lönn; M Ottosson; K Stenlöf; P Björntorp; L Sjöström; B A Bengtsson
Journal:  J Clin Endocrinol Metab       Date:  1997-03       Impact factor: 5.958

3.  Selective expression of an aP2/Fatty Acid Binding Protein 4-Cre transgene in non-adipogenic tissues during embryonic development.

Authors:  Sumithra Urs; Anne Harrington; Lucy Liaw; Deena Small
Journal:  Transgenic Res       Date:  2006-09-02       Impact factor: 2.788

4.  Growth hormone reverses nonalcoholic steatohepatitis in a patient with adult growth hormone deficiency.

Authors:  Yutaka Takahashi; Keiji Iida; Kentaro Takahashi; Shiro Yoshioka; Hidenori Fukuoka; Ryoko Takeno; Mari Imanaka; Hitoshi Nishizawa; Michiko Takahashi; Yasushi Seo; Yoshitake Hayashi; Takuma Kondo; Yasuhiko Okimura; Hidesuke Kaji; Riko Kitazawa; Sohei Kitazawa; Kazuo Chihara
Journal:  Gastroenterology       Date:  2006-12-16       Impact factor: 22.682

5.  Ectopic recombination in the central and peripheral nervous system by aP2/FABP4-Cre mice: implications for metabolism research.

Authors:  Katrin Martens; Astrid Bottelbergs; Myriam Baes
Journal:  FEBS Lett       Date:  2010-02-09       Impact factor: 4.124

6.  Treatment of adults with growth hormone (GH) deficiency with recombinant human GH.

Authors:  B A Bengtsson; S Edén; L Lönn; H Kvist; A Stokland; G Lindstedt; I Bosaeus; J Tölli; L Sjöström; O G Isaksson
Journal:  J Clin Endocrinol Metab       Date:  1993-02       Impact factor: 5.958

7.  Comparing adiposity profiles in three mouse models with altered GH signaling.

Authors:  Darlene E Berryman; Edward O List; Karen T Coschigano; Kevin Behar; Jason K Kim; John J Kopchick
Journal:  Growth Horm IGF Res       Date:  2004-08       Impact factor: 2.372

8.  Age-related changes in body composition of bovine growth hormone transgenic mice.

Authors:  Amanda J Palmer; Min-Yu Chung; Edward O List; Jennifer Walker; Shigeru Okada; John J Kopchick; Darlene E Berryman
Journal:  Endocrinology       Date:  2008-10-23       Impact factor: 4.736

9.  Osteocrin, a novel bone-specific secreted protein that modulates the osteoblast phenotype.

Authors:  Gethin Thomas; Pierre Moffatt; Patrick Salois; Marie-Hélène Gaumond; Rock Gingras; Eric Godin; Dengshun Miao; David Goltzman; Christian Lanctôt
Journal:  J Biol Chem       Date:  2003-10-01       Impact factor: 5.157

10.  Growth hormone action predicts age-related white adipose tissue dysfunction and senescent cell burden in mice.

Authors:  Michael B Stout; Tamara Tchkonia; Tamar Pirtskhalava; Allyson K Palmer; Edward O List; Darlene E Berryman; Ellen R Lubbers; Carlos Escande; Adam Spong; Michal M Masternak; Ann L Oberg; Nathan K LeBrasseur; Richard A Miller; John J Kopchick; Andrzej Bartke; James L Kirkland
Journal:  Aging (Albany NY)       Date:  2014-07       Impact factor: 5.682

View more
  19 in total

1.  Characterization of an intestine-specific GH receptor knockout (IntGHRKO) mouse.

Authors:  Jonathan A Young; Elizabeth A Jensen; Austin Stevens; Silvana Duran-Ortiz; Edward O List; Darlene E Berryman; John J Kopchick
Journal:  Growth Horm IGF Res       Date:  2019-05-03       Impact factor: 2.372

2.  GH Knockout Mice Have Increased Subcutaneous Adipose Tissue With Decreased Fibrosis and Enhanced Insulin Sensitivity.

Authors:  Edward O List; Darlene E Berryman; Mathew Buchman; Elizabeth A Jensen; Kevin Funk; Silvana Duran-Ortiz; Yanrong Qian; Jonathan A Young; Julie Slyby; Savannah McKenna; John J Kopchick
Journal:  Endocrinology       Date:  2019-07-01       Impact factor: 4.736

Review 3.  Mice with gene alterations in the GH and IGF family.

Authors:  Yanrong Qian; Darlene E Berryman; Reetobrata Basu; Edward O List; Shigeru Okada; Jonathan A Young; Elizabeth A Jensen; Stephen R C Bell; Prateek Kulkarni; Silvana Duran-Ortiz; Patricia Mora-Criollo; Samuel C Mathes; Alison L Brittain; Mat Buchman; Emily Davis; Kevin R Funk; Jolie Bogart; Diego Ibarra; Isaac Mendez-Gibson; Julie Slyby; Joseph Terry; John J Kopchick
Journal:  Pituitary       Date:  2021-11-19       Impact factor: 4.107

Review 4.  Covert actions of growth hormone: fibrosis, cardiovascular diseases and cancer.

Authors:  John J Kopchick; Reetobrata Basu; Darlene E Berryman; Jens O L Jorgensen; Gudmundur Johannsson; Vishwajeet Puri
Journal:  Nat Rev Endocrinol       Date:  2022-06-24       Impact factor: 47.564

Review 5.  Growth Hormone and Counterregulation in the Pathogenesis of Diabetes.

Authors:  Xuehong Dong; Lei Su; Mary-Elizabeth Patti
Journal:  Curr Diab Rep       Date:  2022-08-24       Impact factor: 5.430

6.  Disruption of Growth Hormone Receptor in Adipocytes Improves Insulin Sensitivity and Lifespan in Mice.

Authors:  Edward O List; Darlene E Berryman; Julie Slyby; Silvana Duran-Ortiz; Kevin Funk; Elise S Bisset; Susan E Howlett; John J Kopchick
Journal:  Endocrinology       Date:  2022-10-01       Impact factor: 5.051

Review 7.  Mouse models of growth hormone insensitivity.

Authors:  Jonathan Young; Stephen Bell; Yanrong Qian; Caroline Hyman; Darlene E Berryman
Journal:  Rev Endocr Metab Disord       Date:  2020-10-10       Impact factor: 6.514

Review 8.  Growth Hormone and Aging: New Findings.

Authors:  Andrzej Bartke; Erin Hascup; Kevin Hascup; Michal M Masternak
Journal:  World J Mens Health       Date:  2021-02-03       Impact factor: 5.400

Review 9.  An appetite for growth: The role of the hypothalamic - pituitary - growth hormone axis in energy balance.

Authors:  Rebecca Dumbell
Journal:  J Neuroendocrinol       Date:  2022-04-26       Impact factor: 3.870

10.  First use of gene therapy to treat growth hormone resistant dwarfism in a mouse model.

Authors:  Kian Chuan Sia; Shu Uin Gan; Siti Humairah Mohd Rodhi; Zhen Ying Fu; John J Kopchick; Michael J Waters; Kok Onn Lee
Journal:  Gene Ther       Date:  2022-02-01       Impact factor: 4.184

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.